A letter posted to the site of the FDA indicates that the agency approved the new drug application, or NDA, submitted by Teva Neuroscience, as amended, for the use of Austedo XR 6, 12, and 24 mg tablets for the treatment of chorea associated with Huntington’s disease and tardive dyskinesia. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TEVA:
- Axsome facing Auvelity IP challenge ‘not a surprise,’ says BofA
- Axsome received Paragraph IV certification notice on Auvelity ANDA from Teva
- Teva settles price-fixing claims in Florida for $6.73M
- Teva price target raised to $14 from $13 at Barclays
- Israel’s TEVA, PERI Tank on Q4 Earnings; IZRL in Focus